Erlotinib and SBRT in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2017-07-06
Target enrollment:
Participant gender:
Summary
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Stereotactic body radiation therapy may be able to send x-rays
directly to the tumor and cause less damage to normal tissue. Giving erlotinib together with
stereotactic body radiation therapy may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving erlotinib together with stereotactic
body radiation therapy works in treating patients with locally advanced or metastatic
non-small cell lung cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Simmons Cancer Center University of Texas Southwestern Medical Center